Live tape
Top 8, mentions 7d14,333GOOGL2,869 mentions▲ +0.04NVDA2,215 mentions▲ +0.05AMD1,940 mentions▲ +0.08QQQ1,751 mentions▲ +0.05AAPL1,729 mentions▲ +0.05SPY1,560 mentions▲ +0.06TSLA1,164 mentions▲ +0.06SPCX1,105 mentions▲ +0.05

Equity · Healthcare

EWTX

NASDAQ

Edgewise Therapeutics (EWTX)

40 USD +4.77% vs prior close
Edgewise Therapeutics, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for EWTX to draw a line in its place.

Track this symbol on TradingView
Market cap
4.4B USD
P/E (TTM)
4.9
EPS, diluted, year to Dec 2025
−1.63 USD
52-week range
12.66 USD – 48 USD
Avg volume
344.7K

as of Jul 17, 2026

Have Edgewise Therapeutics (EWTX) insiders bought or sold shares recently?

In the 90 days to 9 Nov 2026, Edgewise Therapeutics insiders reported 6 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 11 Nov 2025.

Form 4, 90 days to 9 Nov 2026, newest reported trade 13 Aug 2026

Buys 0Sells 6Net sold $1.90MOther filings 6

Have Edgewise Therapeutics (EWTX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
13 Aug 2026Donovan Joanne M.CMOSell2,919127K USD
12 Aug 2026Russell Alan JChief Scientific OfficerSell5,901258K USD
12 Aug 2026Derakhshan BehradChief Business OfficerSell5,100223K USD
12 Aug 2026Donovan Joanne M.CMOSell6,522286K USD
12 Aug 2026MOORE JOHN RGeneral CounselSell5,016220K USD
12 Aug 2026KOCH KEVINPresident and CEOSell17,971785K USD
Sold6 open-market sales43,429$1.90M
6 other filings in the window: grants, exercises, tax withholding and transfers, not trades
Have Edgewise Therapeutics (EWTX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
01 Oct 2026Fox Jonathan CDirectorAward308
12 Aug 2026Russell Alan JChief Scientific OfficerOption exercise12,812
12 Aug 2026Derakhshan BehradChief Business OfficerOption exercise13,281
12 Aug 2026Donovan Joanne M.CMOOption exercise12,812
12 Aug 2026MOORE JOHN RGeneral CounselOption exercise12,499
12 Aug 2026KOCH KEVINPresident and CEOOption exercise39,844

Which funds hold Edgewise Therapeutics (EWTX)?

8 of the 45 institutional funds we track reported a Edgewise Therapeutics position for the quarter ended 30 Jun 2026 — a combined 187.3M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold Edgewise Therapeutics (EWTX)?
FundPositionSharesValueShares q/q
Baker Bros. AdvisorsTrimmed3,701,719150.4M USD−43.7%
Citadel AdvisorsHeld (±25%)469,70719.1M USD+9.5%
D. E. Shaw & Co.Added189,1157.7M USD+80.3%
Point72 Asset ManagementNew position117,2624.8M USD
Tudor Investment CorpAdded56,9342.3M USD+90.5%
Two Sigma InvestmentsHeld (±25%)49,5482.0M USD−2.6%
AQR Capital ManagementAdded18,456750K USD+116.1%
Marshall WaceTrimmed6,100248K USD−99.1%
Millennium ManagementExited

What has been filed or recorded for Edgewise Therapeutics (EWTX)?

The filings we hold for Edgewise Therapeutics, newest first: 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 30 Sep 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Edgewise Therapeutics (EWTX)?
And
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS 9.65 USD
30 Sep 2026FinancialsTotal assets1.8B USDat period end
30 Sep 2026FinancialsTotal equity1.6B USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.53 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.46 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −1.63 USD
31 Dec 2025FinancialsNet income−167.8M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−1.63 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.39 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.34 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.43 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −1.45 USD

Edgewise Therapeutics (EWTX): frequently asked questions

From live data
4.4B

What is Edgewise Therapeutics’ market cap?

Edgewise Therapeutics is worth 4.4B USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

4.9

What is Edgewise Therapeutics’ P/E ratio?

Edgewise Therapeutics has a price-to-earnings ratio of 4.9, as of 17 Jul 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.

6 sales

Have Edgewise Therapeutics insiders bought or sold shares recently?

In the 90 days to 9 Nov 2026, Edgewise Therapeutics insiders reported 6 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 11 Nov 2025. A further 6 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders

8 of 45

Which funds own Edgewise Therapeutics?

8 of the 45 funds we track reported a Edgewise Therapeutics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Baker Bros. Advisors, Citadel Advisors and D. E. Shaw & Co. See Funds

9.65

When did Edgewise Therapeutics last report earnings?

Edgewise Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 9.65 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  6. SEC EDGARreported earnings figures and scheduled report dates
  7. SEC EDGARValuation computed from SEC EDGAR filings